Precipio, Inc. (PRPO)
USD 5.65
(-0.18%)
USD 5.65
(-0.18%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 384 Thousand USD | -45.76% |
| 2022 | 708 Thousand USD | 25.53% |
| 2021 | 564 Thousand USD | 61.14% |
| 2020 | 350 Thousand USD | 90.22% |
| 2019 | 184 Thousand USD | -6.6% |
| 2018 | 197 Thousand USD | 22.36% |
| 2017 | 161 Thousand USD | 570.83% |
| 2016 | 24 Thousand USD | -52.0% |
| 2015 | 50 Thousand USD | -98.34% |
| 2014 | 3 Million USD | -24.06% |
| 2013 | 3.95 Million USD | -22.29% |
| 2012 | 5.09 Million USD | 31.95% |
| 2011 | 3.85 Million USD | 15.4% |
| 2010 | 3.34 Million USD | -5.86% |
| 2009 | 3.55 Million USD | -25.61% |
| 2008 | 4.77 Million USD | 4.12% |
| 2007 | 4.58 Million USD | 71.63% |
| 2006 | 2.67 Million USD | -10.64% |
| 2005 | 2.99 Million USD | -44.28% |
| 2004 | 5.36 Million USD | -49.3% |
| 2003 | 10.58 Million USD | -14.97% |
| 2002 | 12.44 Million USD | 113.55% |
| 2001 | 5.82 Million USD | 127.07% |
| 2000 | 2.56 Million USD | -34.5% |
| 1999 | 3.91 Million USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 532 Thousand USD | 38.54% |
| 2024 Q2 | 653 Thousand USD | 22.74% |
| 2023 Q3 | 636 Thousand USD | 18.44% |
| 2023 FY | 384 Thousand USD | -45.76% |
| 2023 Q1 | 546 Thousand USD | -22.88% |
| 2023 Q2 | 537 Thousand USD | -1.65% |
| 2023 Q4 | 384 Thousand USD | -39.62% |
| 2022 Q1 | 522 Thousand USD | -7.45% |
| 2022 Q2 | 642 Thousand USD | 22.99% |
| 2022 Q3 | 663 Thousand USD | 3.27% |
| 2022 FY | 708 Thousand USD | 25.53% |
| 2022 Q4 | 708 Thousand USD | 6.79% |
| 2021 FY | 564 Thousand USD | 61.14% |
| 2021 Q1 | 472 Thousand USD | 34.86% |
| 2021 Q2 | 556 Thousand USD | 17.8% |
| 2021 Q3 | 680 Thousand USD | 22.3% |
| 2021 Q4 | 564 Thousand USD | -17.06% |
| 2020 Q4 | 350 Thousand USD | 25.0% |
| 2020 Q3 | 280 Thousand USD | 20.17% |
| 2020 Q2 | 233 Thousand USD | 19.49% |
| 2020 Q1 | 195 Thousand USD | 5.98% |
| 2020 FY | 350 Thousand USD | 90.22% |
| 2019 Q4 | 184 Thousand USD | 1.1% |
| 2019 Q3 | 182 Thousand USD | -3.7% |
| 2019 FY | 184 Thousand USD | -6.6% |
| 2019 Q1 | 149 Thousand USD | -24.37% |
| 2019 Q2 | 189 Thousand USD | 26.85% |
| 2018 Q3 | 175 Thousand USD | 2.34% |
| 2018 FY | 197 Thousand USD | 22.36% |
| 2018 Q4 | 197 Thousand USD | 12.57% |
| 2018 Q2 | 171 Thousand USD | 7.55% |
| 2018 Q1 | 159 Thousand USD | -1.24% |
| 2017 FY | 161 Thousand USD | 570.83% |
| 2017 Q4 | 161 Thousand USD | 62.63% |
| 2017 Q3 | 99 Thousand USD | -8.33% |
| 2017 Q2 | 108 Thousand USD | 620.0% |
| 2017 Q1 | 15 Thousand USD | -37.5% |
| 2016 Q4 | 24 Thousand USD | -33.33% |
| 2016 FY | 24 Thousand USD | -52.0% |
| 2016 Q3 | 36 Thousand USD | -7.69% |
| 2016 Q1 | 44 Thousand USD | -12.0% |
| 2016 Q2 | 39 Thousand USD | -11.36% |
| 2015 Q3 | 3.53 Million USD | 34.82% |
| 2015 FY | 50 Thousand USD | -98.34% |
| 2015 Q4 | 50 Thousand USD | -98.58% |
| 2015 Q2 | 2.61 Million USD | -12.23% |
| 2015 Q1 | 2.98 Million USD | -0.7% |
| 2014 Q4 | 3 Million USD | -16.3% |
| 2014 FY | 3 Million USD | -24.06% |
| 2014 Q3 | 3.59 Million USD | -10.45% |
| 2014 Q2 | 4 Million USD | -1.09% |
| 2014 Q1 | 4.05 Million USD | 2.43% |
| 2013 Q3 | 4.45 Million USD | 1.07% |
| 2013 Q1 | 4.78 Million USD | -6.07% |
| 2013 FY | 3.95 Million USD | -22.29% |
| 2013 Q4 | 3.95 Million USD | -11.16% |
| 2013 Q2 | 4.4 Million USD | -7.86% |
| 2012 Q3 | 4.4 Million USD | 9.3% |
| 2012 Q1 | 4.01 Million USD | 4.02% |
| 2012 FY | 5.09 Million USD | 31.95% |
| 2012 Q4 | 5.09 Million USD | 15.57% |
| 2012 Q2 | 4.03 Million USD | 0.42% |
| 2011 FY | 3.85 Million USD | 15.4% |
| 2011 Q4 | 3.85 Million USD | 16.73% |
| 2011 Q3 | 3.3 Million USD | -0.09% |
| 2011 Q2 | 3.3 Million USD | 4.62% |
| 2011 Q1 | 3.16 Million USD | -5.41% |
| 2010 Q3 | 3.65 Million USD | 10.15% |
| 2010 Q4 | 3.34 Million USD | -8.58% |
| 2010 FY | 3.34 Million USD | -5.86% |
| 2010 Q1 | 3.49 Million USD | -1.63% |
| 2010 Q2 | 3.32 Million USD | -4.95% |
| 2009 FY | 3.55 Million USD | -25.61% |
| 2009 Q1 | 4.84 Million USD | 1.51% |
| 2009 Q2 | 4.63 Million USD | -4.29% |
| 2009 Q3 | 4.13 Million USD | -10.89% |
| 2009 Q4 | 3.55 Million USD | -14.08% |
| 2008 Q1 | 4.29 Million USD | -6.26% |
| 2008 FY | 4.77 Million USD | 4.12% |
| 2008 Q3 | 4.92 Million USD | 6.58% |
| 2008 Q4 | 4.77 Million USD | -2.97% |
| 2008 Q2 | 4.61 Million USD | 7.4% |
| 2007 Q1 | 3.13 Million USD | 17.44% |
| 2007 FY | 4.58 Million USD | 71.63% |
| 2007 Q2 | 3.24 Million USD | 3.35% |
| 2007 Q4 | 4.58 Million USD | 2.09% |
| 2007 Q3 | 4.49 Million USD | 38.51% |
| 2006 Q1 | 2.89 Million USD | -3.31% |
| 2006 Q4 | 2.67 Million USD | 14.38% |
| 2006 Q3 | 2.33 Million USD | -2.79% |
| 2006 Q2 | 2.4 Million USD | -16.88% |
| 2006 FY | 2.67 Million USD | -10.64% |
| 2005 Q2 | 4.58 Million USD | -7.5% |
| 2005 Q3 | 4.1 Million USD | -10.56% |
| 2005 Q4 | 2.99 Million USD | -27.09% |
| 2005 Q1 | 4.95 Million USD | -7.62% |
| 2005 FY | 2.99 Million USD | -44.28% |
| 2004 Q2 | 11.12 Million USD | -0.07% |
| 2004 Q4 | 5.36 Million USD | -25.4% |
| 2004 FY | 5.36 Million USD | -49.3% |
| 2004 Q1 | 11.13 Million USD | 5.22% |
| 2004 Q3 | 7.19 Million USD | -35.37% |
| 2003 Q4 | 10.58 Million USD | -4.17% |
| 2003 Q3 | 11.04 Million USD | -11.69% |
| 2003 FY | 10.58 Million USD | -14.97% |
| 2003 Q1 | 12.51 Million USD | 0.51% |
| 2003 Q2 | 12.5 Million USD | -0.03% |
| 2002 Q2 | 11.89 Million USD | 31.45% |
| 2002 Q3 | 13.13 Million USD | 10.35% |
| 2002 FY | 12.44 Million USD | 113.55% |
| 2002 Q1 | 9.05 Million USD | 55.29% |
| 2002 Q4 | 12.44 Million USD | -5.2% |
| 2001 Q1 | 2.78 Million USD | 8.34% |
| 2001 Q2 | 4.91 Million USD | 76.59% |
| 2001 FY | 5.82 Million USD | 127.07% |
| 2001 Q3 | 5.44 Million USD | 10.85% |
| 2001 Q4 | 5.82 Million USD | 7.07% |
| 2000 Q4 | 2.56 Million USD | -5.96% |
| 2000 Q1 | 2.31 Million USD | 0.0% |
| 2000 Q3 | 2.72 Million USD | 30.54% |
| 2000 FY | 2.56 Million USD | -34.5% |
| 2000 Q2 | 2.09 Million USD | -9.82% |
| 1999 FY | 3.91 Million USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Aspira Women's Health Inc. | 227 Thousand USD | -69.163% |
| bioAffinity Technologies, Inc. | 18.48 Thousand USD | -1977.472% |
| Intelligent Bio Solutions Inc. | 777.53 Thousand USD | 50.613% |
| Standard BioTools Inc. | 20.53 Million USD | 98.13% |
| Inotiv, Inc. | 56.1 Million USD | 99.316% |
| Prenetics Global Limited | 3.12 Million USD | 87.719% |
| Neuronetics, Inc. | 8.09 Million USD | 95.255% |
| Star Equity Holdings, Inc. | 3.42 Million USD | 88.772% |
| Castle Biosciences, Inc. | 7.94 Million USD | 95.165% |
| Psychemedics Corporation | 1.00 USD | -38399900.0% |
| RadNet, Inc. | 1.00 USD | -38399900.0% |
| Exact Sciences Corporation | 127.47 Million USD | 99.699% |
| IDEXX Laboratories, Inc. | 380.28 Million USD | 99.899% |
| iSpecimen Inc. | - USD | -Infinity% |
| OpGen, Inc. | 1.00 USD | -38399900.0% |
| Exagen Inc. | 2.87 Million USD | 86.625% |
| Bionano Genomics, Inc. | 22.89 Million USD | 98.323% |
| CareDx, Inc | 19.47 Million USD | 98.028% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Twist Bioscience Corporation | 32.06 Million USD | 98.802% |
| Guardant Health, Inc. | 61.94 Million USD | 99.38% |
| Biodesix, Inc. | 1.4 Million USD | 72.571% |
| BioNexus Gene Lab Corp. | 1.13 Million USD | 66.25% |
| Natera, Inc. | 40.75 Million USD | 99.058% |
| Fulgent Genetics, Inc. | 5.82 Million USD | 93.41% |
| Sera Prognostics, Inc. | - USD | -Infinity% |
| 23andMe Holding Co. | 12.46 Million USD | 96.919% |
| OPKO Health, Inc. | 65.69 Million USD | 99.415% |
| Personalis, Inc. | 5.66 Million USD | 93.217% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Applied DNA Sciences, Inc. | 330.02 Thousand USD | -16.354% |
| T2 Biosystems, Inc. | 4.81 Million USD | 92.032% |
| Neogen Corporation | 189.26 Million USD | 99.797% |
| Myriad Genetics, Inc. | 20.1 Million USD | 98.09% |
| ICON Public Limited Company | 1.00 USD | -38399900.0% |
| NeoGenomics, Inc. | 24.15 Million USD | 98.41% |
| Star Equity Holdings, Inc. | 3.42 Million USD | 88.772% |
| MDxHealth SA | 2.77 Million USD | 86.182% |
| Prenetics Global Limited | 3.12 Million USD | 87.719% |
| Illumina, Inc. | 587 Million USD | 99.935% |
| DarioHealth Corp. | 5.06 Million USD | 92.414% |
| ENDRA Life Sciences Inc. | 2.62 Million USD | 85.36% |
| Medpace Holdings, Inc. | 1.00 USD | -38399900.0% |
| Mainz Biomed B.V. | 613.63 Thousand USD | 37.422% |
| Trinity Biotech plc | 19.93 Million USD | 98.074% |
| Sotera Health Company | 51.98 Million USD | 99.261% |
| bioAffinity Technologies, Inc. | 18.48 Thousand USD | -1977.472% |